Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | KDM5C | P41229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227922 | 1.00 | ATR (0.46) | ATRALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL15454465 | 0.85 | ALDH1A1 (0.43) | ATRALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL25652299 | 0.84 | ATR (0.36) | ATRALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL31254527 | 0.84 | ATR (0.55) | ATRALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL15231394 | 0.84 | ATR (0.55) | ATRALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL1563063 | 0.84 | ATR (0.44) | ATRALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL27373972 | 0.84 | CA12 (0.46) | ATRALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL4231441 | 0.82 | ALDH1A1 (0.41) | ATRALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL3342272 | 0.82 | ALDH1A1 (0.41) | ATRALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL3828695 | 0.82 | ALDH1A1 (0.41) | ATRALDH1A1KDM4ETSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688753-A1 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688754-A1 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028327-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. | 2026-01-29 | — | — | US | disclosed |
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. | 2026-01-29 | — | — | US | disclosed |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250381182-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12351569-B2 | ALDH-2 inhibitor compounds and methods of use | AMYGDALA NEUROSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4540237-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | Amygdala Neurosciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| WO-2024211686-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2008041118-A2 | PYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008041118-A2 | PYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| CN-101146793-A | Novel heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity | SCHERING CORP (US) | 2008-03-19 | — | — | CN | disclosed |
| CN-101128441-A | Fused aromatic compounds having anti-diabetic activity | MERCK & CO INC (US) | 2008-02-20 | — | — | CN | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| CN-1874769-A | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2006-12-06 | — | — | CN | disclosed |
| CN-1585746-A | Inhibitors of beta-amyloid production and secretion | DAIICHI SEIYAKU CO (JP) | 2005-02-23 | — | — | CN | disclosed |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1368343-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002055518-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028327-A1 | KCC2 POTENTIATORS AND USES THEREOF | HCN1, KCNC1, HCN2 | ATR 3293/4885ALDH1A1 3655/4885KDM4E 3406/4885 |
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | GRIN2C, HCN1, KCNC1 | ATR 3303/4885ALDH1A1 3779/4885KDM4E 3650/4885 |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | ATR 2791/4885ALDH1A1 1313/4885KDM4E 1381/4885 |
| US-20250381182-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | ALDH1A1, ALDH2, ALDH3A1 | ATR 3104/4885ALDH1A1 1/4885KDM4E 924/4885 |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | ATR 2791/4885ALDH1A1 1313/4885KDM4E 1381/4885 |
| US-12351569-B2 | ALDH-2 inhibitor compounds and methods of use | ALDH1A1, ALDH2, ALDH3A1 | ATR 3028/4885ALDH1A1 1/4885KDM4E 970/4885 |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | ATR 4378/4885ALDH1A1 1825/4885KDM4E 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.